These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. [COMPARISON OF PSYCHOPHARMACA LSD-25, BOL-148 AND PSILOCYBIN IN CLINICAL PRACTICE]. KANDIC B; DORDEVIC D Vojnosanit Pregl; 1963 May; 20():275-9. PubMed ID: 14067329 [No Abstract] [Full Text] [Related]
43. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users. McCambridge J; Winstock A; Hunt N; Mitcheson L Eur Addict Res; 2007; 13(1):57-64. PubMed ID: 17172780 [TBL] [Abstract][Full Text] [Related]
44. LSD Flashbacks - The Appearance of New Visual Imagery Not Experienced During Initial Intoxication: Two Case Reports. G Lerner A; Goodman C; Rudinski D; Lev-Ran S Isr J Psychiatry Relat Sci; 2014; 51(4):307-9. PubMed ID: 25841230 [TBL] [Abstract][Full Text] [Related]
45. Adolescent and adult time trends in US hallucinogen use, 2002-19: any use, and use of ecstasy, LSD and PCP. Livne O; Shmulewitz D; Walsh C; Hasin DS Addiction; 2022 Dec; 117(12):3099-3109. PubMed ID: 35978453 [TBL] [Abstract][Full Text] [Related]
46. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews. Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078 [TBL] [Abstract][Full Text] [Related]
48. Therapeutic Applications of Classic Hallucinogens. Bogenschutz MP; Ross S Curr Top Behav Neurosci; 2018; 36():361-391. PubMed ID: 28512684 [TBL] [Abstract][Full Text] [Related]
49. Drug-induced psychosis: emergency diagnosis and management. DiSclafani A; Hall RC; Gardner ER Psychosomatics; 1981 Oct; 22(10):845-50, 855. PubMed ID: 7313045 [No Abstract] [Full Text] [Related]
50. Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment. Doyle MA; Ling S; Lui LMW; Fragnelli P; Teopiz KM; Ho R; Di Vincenzo JD; Rosenblat JD; Gillissie ES; Nogo D; Ceban F; Jawad MY; McIntyre RS Expert Opin Drug Saf; 2022 Jun; 21(6):733-743. PubMed ID: 35426769 [TBL] [Abstract][Full Text] [Related]
51. The Use of Psilocybin in the Treatment of Psychiatric Disorders with Attention to Relative Safety Profile: A Systematic Review. Hodge AT; Sukpraprut-Braaten S; Narlesky M; Strayhan RC J Psychoactive Drugs; 2023; 55(1):40-50. PubMed ID: 35225726 [TBL] [Abstract][Full Text] [Related]
52. Hallucinogen use predicts reduced recidivism among substance-involved offenders under community corrections supervision. Hendricks PS; Clark CB; Johnson MW; Fontaine KR; Cropsey KL J Psychopharmacol; 2014 Jan; 28(1):62-6. PubMed ID: 24399338 [TBL] [Abstract][Full Text] [Related]
53. Three cases of angel's trumpet tea-induced psychosis in adolescent substance abusers. Göpel C; Laufer C; Marcus A Nord J Psychiatry; 2002; 56(1):49-52. PubMed ID: 11869466 [TBL] [Abstract][Full Text] [Related]
54. Does getting high hurt? Characterization of cases of LSD and psilocybin-containing mushroom exposures to national poison centers between 2000 and 2016. Leonard JB; Anderson B; Klein-Schwartz W J Psychopharmacol; 2018 Dec; 32(12):1286-1294. PubMed ID: 30182795 [TBL] [Abstract][Full Text] [Related]
55. The current status of the hallucinogenic drugs. Seal RE Aust N Z J Psychiatry; 1970 Jun; 4(2):64-7. PubMed ID: 5286790 [No Abstract] [Full Text] [Related]
56. [A PSYCHOPATHOLOGICAL STUDY OF THE PSILOCYBIN PSYCHOSIS; COMPARISON WITH THE LSD-25 PSYCHOSIS]. MIYOSHI A Seishin Shinkeigaku Zasshi; 1964 Oct; 66():826-36. PubMed ID: 14286595 [No Abstract] [Full Text] [Related]
57. Hallucinogenic mushrooms. Schwartz RH; Smith DE Clin Pediatr (Phila); 1988 Feb; 27(2):70-3. PubMed ID: 3338231 [TBL] [Abstract][Full Text] [Related]
58. The Association of Salvia divinorum and Psychotic Disorders: A Review of the Literature and Case Series. El-Khoury J; Sahakian N J Psychoactive Drugs; 2015; 47(4):286-92. PubMed ID: 26317561 [TBL] [Abstract][Full Text] [Related]
59. Hallucinogen Persisting Perception Disorder: Etiology, Clinical Features, and Therapeutic Perspectives. Martinotti G; Santacroce R; Pettorruso M; Montemitro C; Spano MC; Lorusso M; di Giannantonio M; Lerner AG Brain Sci; 2018 Mar; 8(3):. PubMed ID: 29547576 [TBL] [Abstract][Full Text] [Related]